Domain Annotation: ECOD Classification ECOD Database Homepage

ChainsFamily NameDomain Identifier ArchitecturePossible HomologyHomologyTopologyFamilyProvenance Source (Version)
De3fzuD1 A: HTHX: HTHH: tetra-helical, lambda repressor-likeT:F:ECOD (20:10:01)
A [auth L]e3fzuL1 A: HTHX: HTHH: tetra-helical, lambda repressor-likeT:F:ECOD (20:10:01)
Ce3fzuC1 A: HTHX: HTHH: tetra-helical, lambda repressor-likeT:F:ECOD (20:10:01)
B [auth H]e3fzuH1 A: UBC-likeX: UBC-likeH: UBC-likeT: UQ_conF:ECOD (20:10:01)

Domain Annotation: CATH CATH Database Homepage

ChainDomainClassArchitectureTopologyHomologyProvenance Source (Version)
D2.60.40.10 Mainly Beta Sandwich Immunoglobulin-like ImmunoglobulinsCATH (4.3.0)
A [auth L]2.60.40.10 Mainly Beta Sandwich Immunoglobulin-like ImmunoglobulinsCATH (4.3.0)
C2.60.40.10 Mainly Beta Sandwich Immunoglobulin-like ImmunoglobulinsCATH (4.3.0)
B [auth H]2.60.40.10 Mainly Beta Sandwich Immunoglobulin-like ImmunoglobulinsCATH (4.3.0)

IMGT Antibody Annotation IMGT Database Homepage

ChainProtein NameDescriptionOrganism NameGene Allele Name(s)Domain Name(s)Receptor TypeReceptor DescriptionProvenance Source
A [auth L],
D
Antibody Fab Fragment L-KAPPA Homo sapiens (human) IGKV1-39*01, IGKV1D-39*01, IGKJ1*01, IGKC*01 V-DOMAIN V-KAPPA, C-DOMAIN C-KAPPA IG FAB-GAMMA-1_KAPPA IMGT (202609-0)
B [auth H],
C
Antibody Fab Fragment VH-CH1 Homo sapiens (human) IGHV3-11*01, IGHV3-21*01, IGHV3-21*02, IGHV3-48*03, IGHV3-74*01, IGHV3-74*02, IGHV3-74*03, IGHV3-23*04, IGHV3-21*04, IGHV3-11*04, IGHV3-21*03, IGHV3-11*05, IGHV3-11*06, IGHJ5*01, IGHG1*01, IGHG1*02, IGHG1*04 V-DOMAIN VH, C-DOMAIN CH1 IG FAB-GAMMA-1_KAPPA IMGT (202609-0)

SAbDab Antibody Annotation SAbDab Database Homepage

ChainChain ClassChain SubclassChain TypeAntigen Name(s) Provenance Source
A [auth L],
D
Light ChainIGKV1 Kappa-SAbDab (2026-03-13)
B [auth H],
C
Heavy ChainIGHV3 --SAbDab (2026-03-13)

Thera-SAbDab Antibody Annotation Thera-SAbDab Database Homepage

ChainNameTargetProvenance Source
A [auth L],
D
Lumiliximab FCER2/CD23Therapeutic SAbDab (2026-03-13)
B [auth H],
C
Lumiliximab FCER2/CD23Therapeutic SAbDab (2026-03-13)